Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in T1 and T2 nasopharyngeal carcinoma

Head and Neck

Volumn 26, Issue 5, 2004, Pages 389-395

  Lu, Jiade J ^a   Shakespeare, Thomas P ^a   Tan, Luke Kim Siang ^a   Goh, Boon Cher ^a   Cooper, Jay S ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brachytherapy; Carcinoma; Nasopharyngeal; Radiation therapy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; ARTICLE; BEAM THERAPY; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FOLLOW UP; HEARING DISORDER; HIGH DOSE RATE INTRACAVITARY BRACHYTHERAPY; HUMAN; HUMAN TISSUE; MALE; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA AND VOMITING; OTITIS MEDIA; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECURRENT CANCER; SIDE EFFECT; SKIN FIBROSIS; SKIN MANIFESTATION; TASTE DISORDER; TREATMENT OUTCOME; TRISMUS; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2342475924     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10398     Document Type: Article

References (23)

1. Al-Sarraf M, LeBlanc M, Giri S, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
2. Cooper JS, Lee H, Torrey M, et al. Improved outcome secondary to concurrent chemoradiotherapy for advanced carcinoma of the nasopharynx: preliminary corroboration of the Intergroup experience. Int J Radiat Oncol Biol Phys 2000;47:861-866.
3. Sanguineti G, Geara F, Garden A, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985-996.
4. Marks JE, Bedwinek JM, Lee F, et al. Dose-response analysis for nasopharyngeal carcinoma: an historical perspective. Cancer 1982;50:1042-1050.
5. Vikram B, Mishra UB, Strong EW, et al. Patterns of failure in carcinoma of the nasopharynx: I. Failure at the primary site. Int J Radiat Oncol Biol Phys 1985;11:1455-1459.
6. Wang CC. Improved local control of nasopharyngeal carcinoma after intracavitary brachytherapy boost. Am J Clin Oncol 1991;14:5-8.
7. Chang JT, See LC, Tang SG, et al. The role of brachytherapy in early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1996;36:1019-1024.
8. Heng DMK, Wee J, Fong KW, et al. Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999;86:1912-1920.
9. Levendag PC, Schmitz, PI, Jansen PP, et al. Fractionated high-dose rate brachytherapy in primary carcinoma of the nasopharynx. J Clin Oncol 1998;16:2213-2220.
10. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
11. Syed AMN, Puthawala AA, Damore SJ, et al. Brachytherapy for primary and recurrent nasopharyngeal carcinoma: 20 years' experience at Long Beach Memorial. Int J Radiat Oncol Biol Phys 2000;47:1311-1321.
12. Bedwinek JM, Perez CA, Keys DJ. Analysis of failures after definitive irradiation for epidermoidcarcinoma of the nasopharynx. Cancer 1980;45:2725-2729.
13. Zhang YW, Liu TF, Fi CX. Intracavitary radiation treatment of nasopharyngeal carcinoma by the high dose rate afterloading technique. Int J Radiat Oncol Biol Phys 1989;16:315-318.
14. Teo PML, Leung SF, Lee WY, et al. Intracavitary brachytherapy significantly enhances local control of early T-stage nasopharyngeal carcinoma: the existence of a dose-tumor-control relationship above conventional tumoricidal dose. Int J Radiat Oncol Biol Phys 2000;46:445-458.
15. Ozyar E, Yildz F, Akyol FH, et al. Adjuvant high-dose-rate brachytherapy after external beam radiotherapy in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2002;52:101-108.
16. Yang TS, Ng KT, Wang HM, et al. Prognostic factors of locoregionally recurrent nasopharyngeal carcinoma - A retrospective review of 182 cases. Am J Clin Oncol 1996;19:337-343.
17. Russell JD, Bleach NR, Glaser M, et al. Brachytherapy for recurrent nasopharyngeal and nasoethmoidal tumors. J Laryngol Otol 1993;107:115-120.
18. Yan JH, Hu YH, Gu XZ. Radiation therapy of recurrent nasopharyngeal carcinoma. Acta Radiol Oncol 1983;22:23-28.
19. DeNittis AS, Liu L, Rosenthal DI, et al. Nasopharyngeal carcinoma treated with external radiotherapy, brachytherapy, and concurrent/adjuvant chemotherapy. Am J Clin Oncol 2002;25:93-95.
20. Lee N, Hoffman R, Phillips T, et al. Managing nasopharyngeal carcinoma with intracavitary brachytherapy: one institution's 45-year experience. Brachytherapy 2002;1:74-82.
21. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1997.
22. Nag S, Cano ER, Demanes DJ, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1190-1198.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.